SCHEMBL15523145

SCHEMBL15523145

O=C1CC2(CCC2)c2ccccc2N1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 1/20 0.49
PLD1 Q13393 1/20 0.43
MAPT P10636 1/20 0.42
PDK2 Q15119 2/20 0.41
AHR P35869 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MAPK1 P28482 1/20 0.41
NPC1 O15118 1/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
PDK4 Q16654 1/20 0.40
BACE1 P56817 1/20 0.40
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
IDO1 P14902 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30412849 0.95 PDE7A (0.56) PDE7APLD1MAPTPDK2AHR
SCHEMBL13641107 0.95 PDE7A (0.56) PDE7APLD1MAPTPDK2AHR
SCHEMBL2101880 0.86 BACE1 (0.49) PDE7APLD1MAPTPDK2AHR
Hydrochloric Acid SCHEMBL2402549 0.84 BACE1 (0.47) PDE7APLD1MAPTPDK2AHR
SCHEMBL12568554 0.83 BRD4 (0.45) PDE7APLD1PDK2AHRNPC1
Hydrochloric Acid SCHEMBL6636857 0.82 BACE1 (0.47) PDE7APLD1MAPTPDK2AHR
SCHEMBL13314948 0.82 PLD1 (0.49) PDE7APLD1PDK2AHRNPC1
SCHEMBL12084780 0.81 BACE1 (0.44) PDE7APLD1MAPTPDK2AHR
SCHEMBL8524452 0.79 PDE7A (0.50) PDE7AMAPTPDK2AHRMEN1
SCHEMBL14156745 0.78 PLD1 (0.52) PDE7APLD1PDK2KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200283439-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2020-09-10 US disclosed
US-20190071443-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2019-03-07 US disclosed
US-10118926-B2 Tricyclic quinoline and quinoxaline derivatives AbbVie Deutschland GmbH & Co. KG (DE) 2018-11-06 US disclosed
US-20140080816-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2014-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080816-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES HTR2C, HTR2A, HTR5A PDE7A 420/4885PLD1 2139/4885MAPT 3416/4885
US-20200283439-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES HTR2C, HTR2A, HTR5A PDE7A 420/4885PLD1 2139/4885MAPT 3416/4885
US-10118926-B2 Tricyclic quinoline and quinoxaline derivatives HTR2C, HTR2A, HTR5A PDE7A 420/4885PLD1 2139/4885MAPT 3416/4885
US-20190071443-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES HTR2C, HTR2A, HTR5A PDE7A 420/4885PLD1 2139/4885MAPT 3416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.